ArticleThe Journal of clinical investigation2020

Glibenclamide reverses cardiovascular abnormalities of Cantu syndrome driven by KATP channel overactivity.

Conor McClenaghan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.